Obefazimod in patients with moderate-to-severely active ulcerative colitis: efficacy and safety analysis from the 96-week open-label maintenance phase 2b studySéverine Vermeire, Bruce E. Sands, Julien Santo et al.|Journal of Crohn s and Colitis|2025Cited by 10